Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint is the author/funder, who has granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.

Until the paper has been able to undergo proper copyediting, typesetting, and author proofing, readers should be aware that the specific preprint information below may contain errors and has not been finalized by authors.

**BCG vaccine and COVID-19: Implications for infection prophylaxis and cancer immunotherapy**

Madhuri Koti*, Alvaro Morales, Charles H. Graham, D. Robert Siemens

**Keywords:** BCG, Interferon, Tertiary Lymphoid Structure, Bladder Cancer, COVID-19

**Affiliations:** 1) Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, K7L 3N6, Canada, 2) Department of Obstetrics and Gynecology, Queen’s University, Kingston, Ontario, K7L 3N6, Canada, 3) Cancer Biology and Genetics Division, Queen’s Cancer Research Institute, Queen’s University, Kingston, Ontario, K7L 3N6, Canada, 4) Department of Urology, Queen’s University, Kingston, Ontario, K7L 3N6, Canada

**Corresponding Author:** Madhuri Koti, DVM, MVSc, PhD, Assistant Professor, Department of Biomedical and Molecular Sciences and Obstetrics and Gynecology, Queen’s University, Kingston, Ontario K7L3N6 Canada, kotim@queensu.ca
Abstract
The COrona Virus Induced Disease-19 (COVID-19) pandemic has killed over 400,000 people globally. Ecological evidence indicates that countries with national universal Bacillus Calmette-Guérin (BCG) vaccination programs for tuberculosis (TB) prevention have a much lower incidence of severe COVID-19 and mortality compared to those that do not have such programs. BCG is a century old vaccine used for TB prevention via infant/childhood vaccination in low to middle income countries with high infection prevalence rate and is known to reduce all cause neonatal mortality. BCG remains the standard immunotherapy treatment for high-risk non-muscle invasive bladder cancer patients globally for more than 44 years. Several trials are therefore, investigating BCG as a prophylactic against COVID-19 in health care workers and the elderly. In this commentary, we discuss the potential mechanisms that may underlie BCG associated heterologous protection with a focus on tertiary lymphoid structure (TLS) organogenesis. Given the significance of TLSs in mucosal immunity, their association with positive prognosis and response to immune checkpoint blockade with a critical role of Type I interferon (IFN-1) in inducing these, we also discuss potentiating TLS formation as a promising approach to enhance anti-tumour immunity. We propose that lessons learnt from BCG immunotherapy success could be applied to not only augment such microbe-based therapeutics but also lead to similar adjunctive IFN-1 activating approaches to improve response to immune checkpoint blockade therapy in cancer.
Main text

The observation that microbes could curb cancer growth was made over 4000 years ago when incisions on tumours led to infection mediated spontaneous regression. In modern medicine, the therapeutic potential of microbes, or their components, against cancer was first demonstrated by William Coley in 1891. Although Coley’s toxins did not come into wide clinical practice due to inconsistencies in the type of cancers treated, routes of administration and variable outcomes from this clinical experience established the proof-of-concept that stimulating the immune system using microbes or their components can be an adjunctive treatment to surgery and cytotoxic therapy. Although this was followed by sporadic successes in other solid tumours, a major success pioneering the field of cancer immunotherapy was introduction of intravesical administration of Bacillus Calmette-Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC) [1]. This was one of the very few initial testaments of benefits from weakened or modified microbes and their specific molecular patterns for anti-tumour immune sensitization. Despite ongoing global shortages, BCG immunotherapy remains the gold standard treatment for NMIBC. Over the last 100 years, BCG vaccine has been the only tuberculosis (TB) preventative strategy and is quite eloquently described as “the vaccine that keeps on giving” [2]. Infant/childhood BCG vaccination via intradermal administration continues to be practiced in several countries to prevent tuberculosis [2]. An intriguing association between BCG vaccination and incidence from the ongoing Corona Virus Induced Disease-19 (COVID-19) is a recent stirring albeit a controversial observation. Countries with national vaccination programs (e.g. India, Korea, Japan) for TB prevention, using BCG vaccine, showed a much lower morbidity and mortality from severe COVID-19 compared to those (e.g. Italy, United States, United Kingdom) that do not have such policies [3]. Although this observation was not confirmed by others [4], an immediate response to this ecological finding was initiation of COVID-19 clinical trials evaluating BCG (https://clinicaltrials.gov/ct2/results?cond=BCG+and+COVID-19) and its recombinant form VPM1002 (https://clinicaltrials.gov/NCT04387409), to protect health care workers and the elderly.

BCG remains as one of the best-known vaccines associated with beneficial and heterologous protection from other diseases. The “pathogen agnostic” effects of BCG span from reducing sepsis associated mortality [2], protection against other forms of TB, potentiating anti-viral (RSV, yellow fever caused by an RNA virus) immune responses and most importantly reducing cancer recurrence and progression [5]. This non-specific effect of BCG is described to be at least partially mediated via innate immune memory/trained immunity through microbe-induced epigenetic changes in cells of the innate and adaptive immune systems [5]. While trial outcomes from BCG vaccination induced protection of
health care workers from COVID-19 is awaited to further support this interesting and promising association, several questions arise; 1) Is this protective effect age and sex dependent? 2) How long does the protection last? 3) Can BCG synergize with currently approved immunomodulatory agents? 4) Given the variability in immune cell composition across tissues, is the effect location/tissue type dependent? 5) Does the dose, route, duration, number and frequency of administration weight on the effect? 6) Does the host genetics influence response? 7) Will the strain of BCG vaccine induce a variable response? 8) Will lung associated co-morbidities cause a deleterious effect due to a chronic inflammatory state and most importantly, 9) How could these investigations impact NMIBC patient/cancer treatment?

While re-visiting the parallels of anti-viral and anti-cancer immunity, interferons (IFN) undoubtedly lie at a major intersection between these two pathologies. Viral infection antagonizes cytosolic innate sensing pathways such as the Retinoic acid-inducible gene (RIG-1) and cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-STimulator of INterferon Genes (STING) pathways to evade protective IFN response. Mimicking such viral immune evasion mechanisms, cancer cells often adapt to an impaired IFN-1 signalling and thus modulate the associated microenvironment towards a suppressive phenotype conducive to their growth and metastasis. Both Type I and II IFN (IFN-α/β and IFN-γ, respectively) are critical to these effects and therefore, effort has focussed on their direct or indirect activation via vaccination and/or therapeutic introduction in order to induce or magnify a protective IFN response.

This brings us to the question of how does BCG impart its non-specific protective effect against viral infections or its anti-cancer effect and are they IFN dependent? Studies from Netea and colleagues have extensively investigated and explained this concept and role of innate immune memory within macrophages [5]. Yao and colleagues further demonstrated that at mucosal sites, CD8+ T cell help was indispensable for priming of such memory within the lung resident alveolar macrophages [6]. Subsequent downstream effects extrinsic to macrophages, such as chemokine mediated immune cell recruitment to the site of infection/inflammation and further activation of the adaptive immune responses and the influence of tissue specific immune microenvironment are some key factors to the overall favorable outcomes that depend on the initial magnitude of macrophage priming. In our effort to further gain a deeper understanding of BCG induced protective effects and enhance those, we must consider the unique pathogenesis of Mycobacterial infection and host responses towards controlling its spread. One such unique feature that is seen across the spectrum of various TB states, is granuloma formation [7]. Granuloma formation is considered to be a hallmark of Mycobacterial infection. *Mycobacterium tuberculosis* (*M.tbc*) induced granuloma and is constituted by an aggregate of
macrophages and lymphocytes and develops as a result of host immune responses to contain the bacterial spread. Interestingly, TB associated/pathogenic *Mycobacteria* induced protective, chronic granuloma also exhibits remarkable similarities to an ectopic/tertiary lymphoid structure (TLS), a predominant feature of mucosa associated lymphoid tissue containing innate and adaptive immune cells with similar architecture as seen in a canonical germinal center in secondary lymphoid organs [7]. Indeed, IFN-1 signalling and downstream immune cell chemotaxis to the site of infection, are central to the formation of these TLSs and maturation of B cells including class switching and affinity maturation within these [8].

Following birth, TLSs develop at mucosal sites (e.g. respiratory, gut and urogenital tract). TLSs also form as a result of exposure to normal commensal and pathogenic microbes and chronic inflammation (e.g. chronic obstructive pulmonary disease; COPD and cancer) and generally provide heterologous humoral immune protection [8]. Higher frequency of these TLSs, also known as induced bronchus associated lymphoid tissues (iBALTs) in the respiratory mucosa, is protective against respiratory infections such as *Influenza A virus*, *SARS-CoV* and *M.tbc* [8]. The proximity of vaccine-induced iBALTs to respiratory pathogens leads to rapid B-cell maturation, antibody production and T cell priming. Mucosal vaccination with BCG (either lung or bladder) also leads to delayed granuloma/iBALT formation as well as B cell activation, reminiscent of pathogenic Mycobacteria associated granuloma. In contrast, pathogenic iBALTs also develop in autoimmune diseases and in respiratory pathologies such as asthma, smoking, hypertension, COPD. Irrespective of the initial insult/challenge, IFN-1 is critical to TLS organogenesis [8].

Similar to mucosal vaccination associated granuloma formation, in the case of NMIBC, BCG delivered into the bladder lumen/mucosa also leads to granuloma formation [9, 10]. To compensate for lack of response to BCG given its inability to induce IFN-1 activation, exogenously delivered recombinant IFN-α has been extensively trialed in this cancer [10]. Adenoviral vector expressing IFN-α2b is also currently in Phase III trials (https://clinicaltrials.gov/NCT02773849). Over the past few years, several studies have been conducted to identify factors underlying reduced efficacy of BCG to activate an IFN-1 response.

BCG is derived via attenuation of *Mycobacterium bovis (M.bovis)*. The loss of early secretory antigenic target secretion system-1 (ESX-1), one of the immunodominant antigens, as a result of attenuation for vaccine preparation, impairs the ability of BCG to activate the cGAS-STING/IRF3 RIG/MAVS/IRF7 cytosolic nucleic acid sensing pathways [11]. As such, there is minimal IFN-β production, while some protection is imparted through cytokine induction and downstream immunologic effects via
NLRP3 inflammasome activation within macrophages, dendritic cells and epithelial cells [11]. To compensate for this IFN-1 activation defect, several recombinant versions of BCG have been generated. VPM1002 is a promising recombinant BCG that activates the AIM2 inflammasome and the STING pathway and has also demonstrated to impart significantly higher protection over conventional BCG in Phase I and II trials [12]. Indeed, VPM1002 is also being trialed in health care workers and the elderly to protect against severe COVID-19 disease. While the outcomes of these trials are awaited, based on previous studies, it is relevant and timely to hypothesize that mucosal delivery of BCG combined with a STING pathway activator as an adjuvant may lead to the desired neogenesis of iBALTs in the respiratory mucosa that may offer enhanced better protection against COVID-19 (Figure 1). Most importantly, as the positive impact of B cells in anti-tumour immunity is being recognized, specifically those that are associated with TLSs formed post immune checkpoint blockade therapy in sarcoma, melanoma and lung cancer, further research is warranted towards their therapeutic induction across cancers [13]. Heterologous protection similar to BCG induced trained immunity, has also been reported with respect to measles and polio vaccines [14, 15]. Given the critical role of dendritic cells in TLSs and their potent IFN-1 producing characteristic, microbe-based therapeutics, such as oncolytic viruses could also investigate similar immune memory associated effects to increase durable anti-tumour immune response.

The wide spectrum of protection using BCG vaccine against non-related pathogens and cancer to enhance innate immunity and bridge adaptive immune responses, emphasizes the urgent need to re-visit such microbe-based combination therapeutics for cancer treatment, specifically via local administration. Unfortunately, the ongoing global shortage of BCG has affected routine management of bladder cancer patients in addition to compromising infant vaccination in some countries. The lessons learnt from BCG induced non-specific protection across infectious and non-infectious diseases could be adapted towards development of similar microbe-based therapies such as oncolytic viruses, *Bifidobacteria* and others that activate IFN-1 via the STING pathway and potentially mediate innate immune sensitization for immune checkpoint blockade via induction of TLS formation.

**Declarations**

**Authors’ contributions and acknowledgements**

MK wrote the manuscript. AM, CHG and DRS reviewed and edited the manuscript.
Funding
This work was supported by Queen’s University Research Initiation Grant and the Ontario Ministry of Research Innovation and Science, Early Researcher Award to MK.

Availability of data and material
All citations used in the manuscript are listed in the reference section.

Ethics approval and consent to participate
There is no consent associated with this manuscript

Consent for publication
All authors have consented for the publication.

Competing interests
The authors declare no competing interests.
References


Figure 1. Hypothetical diagram showing enhanced protection by intranasally delivered BCG (in combination with a STING pathway activator) or with recombinant BCG (VPM1002), against SARS-CoV2 viral infection. *iBALT*: induced Bronchus Associated lymphoid Tissue, *TLS*: Tertiary Lymphoid Structure